Miriam Mwachinga: Let’s Focus More on Rare Diseases and Their Impact on Quality of Life
Miriam Mwachinga, General Practitioner, Internal Medicine, Medical Affairs at Healthcare Industry, Pharmaceutical Ind, shared on LinkedIn:
”One of my college professors once made a comment that has stayed with me over the years.
Diseases that affect 1 in a million often seem insignificant, but the impact on your quality of life if you are that 1 person in a million is huge.
Rare diseases tend to be overlooked because the cost: benefit ratio doesn’t make economic sense when it comes to drug development, but that doesn’t make them any less significant.
Hemophilia A is the most common genetic X-linked disease, but still far behind when it comes to clinical research.
With Rare Disease Day coming up later this month, let’s all focus a bit more on rare diseases.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question
-
Oct 20, 2026, 04:04Sadia Kamal: Honored to Receive the Outstanding Abstract Award at the 20th Midwest Platelet Conference
-
Oct 20, 2026, 04:03Yu-Hsuan Chen: One Antibody, Two Diseases from FcRn Biology to Clinical Translation
-
Oct 20, 2026, 03:49Domenico Simone Castiello: Rethinking Prolonged DAPT in Multivessel PCI – Insights from the DAPT-MVD Trial
-
Oct 20, 2026, 03:37Rucha Patil: Scaling POC Diagnostics for Haemophilia A and VWD Across India
-
Oct 20, 2026, 03:31Zena Vexler: Targeting Neutrophil Elastase and NETosis to Mitigate Infection-Triggered Childhood Stroke
-
Oct 20, 2026, 03:24Chaza Alaji: Diagnosing Protein C and Protein S Deficiency
-
Oct 20, 2026, 03:24Mou Nandi: How Maternal Health During Pregnancy May Shape Infant Development
-
Oct 20, 2026, 03:13Sumyea Kabir: Pre-Analytical Quality in Phlebotomy – Preventing In Vitro Hemolysis